Emerging Diet Bias dimension Mixed tiers

Small Intestinal Bacterial Overgrowth (SIBO)

Summary

Small Intestinal Bacterial Overgrowth (SIBO) occurs when excessive bacteria colonize the small intestine, where relatively few should normally exist. These bacteria ferment food before proper absorption, producing gases, toxins, and inflammation that cause bloating, malabsorption, and systemic symptoms like fatigue and brain fog. SIBO is often the hidden reason why people following "perfect" diets still experience persistent digestive issues and paradoxical reactions to healthy foods like fiber and fermented foods.

The condition affects 2.5-22% of the general population and up to 85% of people with IBS, depending on diagnostic criteria. While SIBO is recognized by mainstream gastroenterology, it's often undertested, and current diagnostic methods have significant limitations. Treatment can be effective but requires addressing underlying causes like impaired gut motility, acid suppression, or structural issues to prevent recurrence.

Why Emerging

Tier 2 for the underlying biology — migrating motor complex impairment from food poisoning/PPIs/opioids/diabetes/hypothyroidism is well-characterised, and downstream consequences (carbohydrate fermentation producing hydrogen/methane, bile acid deconjugation, B12 consumption, endotoxin production) are mechanism-validated. Rifaximin shows 40–70% response rates with FDA approval for IBS-D. Tier 3 specifically for diagnostic certainty: breath-test sensitivity 31–68%, specificity 44–100% — the field cannot reliably distinguish "true SIBO" from related dysmotilities. Herbal protocols (berberine, oregano oil, allicin) show comparable response rates to rifaximin in clinical trials but heterogeneity is high. Recurrence rates remain high without addressing motility issues. Industry-bias dimension: the SIBO testing/treatment industry has expanded faster than the diagnostic standard has consolidated. Not Tier 2 overall because population-prevalence claims (2.5–22% general, 85% in specific conditions) vary dramatically with test method, suggesting a label more diffuse than the underlying biology supports.

Tier 2 for underlying biology and treatment efficacy; Tier 3 for diagnostic certainty

Practical takeaway

If you experience bloating after eating regardless of food type, especially if healthy foods like fiber make symptoms worse, consider SIBO evaluation through breath testing with a knowledgeable practitioner. Focus first on addressing underlying causes like PPI use, hypothyroidism, or poor meal spacing (aim for 4-5 hour gaps between meals). Treatment typically involves antimicrobials (pharmaceutical or herbal) combined with prokinetics to restore normal gut motility and prevent recurrence.

Key findings

SIBO causes bloating within 30-90 minutes of eating, regardless of food type, and symptoms often worsen with fiber, prebiotics, and fermented foods
The condition is strongly associated with IBS (30-85% prevalence), hypothyroidism (54%), diabetes with neuropathy (40-60%), and post-infectious gut issues
Rifaximin antibiotic treatment shows 40-70% response rates, but recurrence occurs in 44% of cases within 9 months without addressing underlying causes
Herbal antimicrobial protocols show comparable effectiveness to pharmaceutical treatments in clinical studies
The migrating motor complex (MMC) - the gut's natural "cleansing wave" between meals - is often impaired in SIBO, requiring meal spacing and prokinetic support

Evidence detail

SIBO develops when the small intestine's normal bacterial control mechanisms fail. The migrating motor complex (MMC) normally creates cleansing waves between meals that sweep bacteria toward the colon, but this system can be damaged by food poisoning, medications like PPIs and opioids, diabetes, hypothyroidism, or chronic stress. Structural issues from surgery, adhesions, or ileocecal valve dysfunction can also create bacterial stagnation.

Once established, the bacteria ferment carbohydrates producing hydrogen and methane gases that cause bloating and distension. They also deconjugate bile acids leading to fat malabsorption, damage brush border enzymes causing carbohydrate intolerance, consume vitamin B12, and produce inflammatory endotoxins that contribute to systemic symptoms like fatigue and brain fog.

Three main subtypes exist: hydrogen-dominant SIBO (associated with diarrhea), methane-dominant or IMO (associated with constipation), and hydrogen sulfide SIBO (less well characterized). Diagnosis relies primarily on lactulose or glucose breath testing, though these tests have limitations with sensitivity ranging from 31-68% and specificity from 44-100%.

Treatment effectiveness varies significantly based on addressing underlying causes. Rifaximin, a minimally absorbed antibiotic, shows 40-70% response rates and is FDA-approved for IBS-D. Herbal protocols using berberine-containing herbs, oregano oil, and allicin have shown comparable effectiveness in clinical trials. However, without addressing motility issues through prokinetics, meal spacing, and underlying conditions, recurrence rates remain high.

The elemental diet, consisting of pre-digested liquid nutrients for 2-3 weeks, shows 80-84% efficacy but is difficult to adhere to and reserved for treatment-resistant cases. Long-term dietary restriction is not recommended, as it can worsen the underlying motility issues and create problematic relationships with food.

Sources (6)

Open in the Library: search, filter, every entry →